AMCP’s Susan Cantrell Suggests Collaborative Solutions to Address High Drug Prices and Healthcare Disparities in Underserved Communities
In this second part of a video series, AMCP CEO Susan Cantrell addressed the impact of high prescription drug prices on underserved communities, highlighting disparities in access caused by the pandemic's effects on minority populations. On the industry blame debate, she urged collaborative solutions, mentioning AMCP's engagement with diverse stakeholders to find comprehensive, patient-centric solutions and advocate for policy changes like the MVP Act to address rising costs and access challenges.
Susan Cantrell, CEO of AMCP, discussed the impact of high prescription drug prices on underserved communities, highlighting disparities in medication access.
Due to the effects of the pandemic, the disproportionate impact on minority populations highlighted existing challenges in healthcare access. For example, lower socioeconomic status poses significant hurdles in accessing medicine and healthcare.
Cantrell shared that comprehensive drug coverage availability through government programs and exchanges is crucial as high costs of prescription drugs becomes a significant barrier for underserved communities.
In addition, she suggested benefit design and cost-sharing models need reevaluation to ensure equitable access for all Americans at an affordable cost.
When asked about the debate between pharmaceutical and pharmacy benefit management (PBM) industries blaming each other for high drug prices, Cantrell advocated for collaborative solutions instead of playing the blame game.
She shared that AMCP engages stakeholders across the healthcare ecosystem to find comprehensive, long-term solutions.
Emphasizing collaboration and creative problem-solving, AMCP also conducts partnership forums to address rising costs and access issues.
Cantrell's approach focuses on bringing diverse stakeholders together, fostering open dialogue, and advocating for policies that prioritize patient access to medicines.
Jack Linehan of Epstein Becker Green Discusses Drug Coupons, Accumulators
July 9th 2020In this week's episode of Tuning Into The C-Suite podcast, Senior Editor Peter Wehrwein has a conversation with John "Jack" Linehan, a lawyer for Epstein Becker Green, about coupons and accumulators. Jack is an expert on drug distribution and reimbursement, and few people know as much about coupons and accumulators as he does. Peter and Jack go over some of the basics, who is advantaged and disadvantaged, and then dive into some the details on CMS regulations and how recent proposed changes to Medicaid best price rules would, if finalized, affect coupons and accumulators.
Listen
